Giant Cell Arteritis: Ustekinumab Shows Activity in Early TrialGiant Cell Arteritis: Ustekinumab Shows Activity in Early Trial

Ustekinumab was associated with lower steroid doses in some patients with GCA and reduced arterial wall thickening. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news
More News: Health | Rheumatology | Stelara